Archives
-
Fluorouracil: Modeling Response Heterogeneity
2026-09-07
Fluorouracil and 5-Fluorouracil are powerful tools for studying thymidylate synthase blockade, replication stress, and variable tumor response. This article translates colorectal cancer evolution research into a heterogeneity-aware framework for mechanistic assays and preclinical study design.
-
In Vitro Drug Response Evaluation in Cancer
2026-09-07
Hannah Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. By separating growth inhibition from cell killing and considering their timing, the study provides a more precise framework for interpreting drug responses and designing mechanistic cancer assays.
-
Angiotensin II: Mechanism and Research Use
2026-09-05
Angiotensin II, also called Asp-Arg-Val-Tyr-Ile-His-Pro-Phe, is an endogenous octapeptide and potent vasopressor that activates angiotensin GPCRs. Its receptor signaling supports hypertension mechanism study, vascular remodeling, and controlled cardiovascular disease models, but experimental dose and model context determine interpretation.
-
Mitomycin C Workflows for Apoptosis Research
2026-09-04
Mitomycin C turns DNA adduct formation into a controllable platform for DNA replication inhibition, apoptosis mapping, and TRAIL sensitization. This practical guide covers dosing, combination design, cell-state controls, and troubleshooting across PC3 and colon cancer model workflows.
-
AZD2461 Assay Design for Reliable PARP Studies
2026-09-04
This scenario-based guide explains how AZD2461, SKU A4164, can support interpretable cell viability, proliferation, and cytotoxicity assays in breast cancer research. It connects PARP biology with practical dose design, formulation control, endpoint selection, and evidence-based reagent sourcing.
-
ATRA Reverses Cisplatin-Associated PARP Resistance
2026-09-03
A 2025 study in Molecular Cancer Therapeutics shows that all-trans retinoic acid can reduce cisplatin-induced resistance to PARP inhibition in epithelial ovarian cancer models. Sequential cisplatin treatment followed by niraparib maintenance with ATRA improved tumor control and survival in preclinical systems, while implicating ALDH1A1, NAMPT, PARP1, CHEK1, and intracellular NAD+ as components of the resistant state.
-
AZD1390: ATM Kinase Inhibitor Workflow
2026-09-03
AZD1390 enables concentration-controlled ATM inhibition for radiation, replication-stress, and glioblastoma models. Its strongest use-case is a mechanistic workflow that connects double-strand-break signaling with emerging REV1–DHX36 control of G-quadruplex DNA tolerance.
-
AZD1390 ATM Kinase Inhibitor Workflow
2026-09-02
AZD1390 enables precise interrogation of ATM-dependent DNA damage signaling and radiation response in glioma and lung cancer models. This workflow combines validated radiosensitization conditions with exploratory assays for G-quadruplex replication stress, helping distinguish checkpoint failure from direct repair defects.
-
Sulfisomidine: A Matrix-Aware Research Framework
2026-09-02
Sulfisomidine, also known as sulfamethin, is more than a sulfonamide antibacterial: it is a mechanistic probe for folate biology, hPON1 inhibition, and transformation-product research. This guide connects enzyme assay design with environmental fate analysis to improve interpretation and reproducibility.
-
Geneticin, G-418 Sulfate: Selection Guide
2026-09-01
Geneticin, G-418 Sulfate (SKU A2513) provides selective pressure for cells carrying a neomycin resistance gene and can support defined antiviral experiments involving Dengue virus serotype 2. Its working concentration must be optimized by cell type and assay; the dossier range is not a substitute for a cell-line-specific kill curve or cytotoxicity control.
-
Platelet Extravasation into Tumors: Molecular Control
2026-09-01
The reference study establishes that platelet entry into tumors is an actively regulated process rather than passive leakage from abnormal vessels. It identifies stromal CXCL12–CXCR4 signaling, platelet FAK and PECAM-1, and distinct granule-release pathways as separable controls of platelet trafficking, vascular integrity, and tumor growth.
-
Matrine: A Mechanism-to-Assay Research Map
2026-08-31
Matrine is a Sophora-derived alkaloid with interconnected anticancer, apoptotic, and anti-inflammatory effects. This evidence-led guide separates established observations from mechanistic hypotheses and translates recent thymoma findings into better assay-selection decisions.
-
(S)-(+)-Dimethindene maleate: Practical Guide
2026-08-31
(S)-(+)-Dimethindene maleate is a research tool for evaluating M2 muscarinic and histamine H1 receptor antagonism when subtype-aware assay design is required. This dossier-based guidance covers preparation, controls, and interpretation; the compound is not intended for diagnostic, clinical, or medical use.
-
In Vitro Drug Response Metrics in Cancer
2026-08-30
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent components of an anticancer response. This framework supports more informative experimental designs by requiring researchers to consider response magnitude, mechanism, and timing rather than relying on a single viability endpoint.
-
Early Life Adversity, Oxytocin, and Innate Defense
2026-08-29
A 2026 Communications Biology article links early life adversity with impaired looming-evoked defensive behavior in mice and identifies deficient oxytocin signaling in the superior colliculus as a mechanistic contributor. The study combines developmental stress modeling, behavioral analysis, receptor knockdown, circuit investigation, and intranasal oxytocin rescue to connect early experience with innate threat processing.